- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Alvotech to Manufacture Prestige's Biosimilars
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Iceland-based Alvotech and Singapore-based Prestige Biopharma have entered a contract manufacturing partnership for Prestige’s biosimilars.
Under the partnership, Alvotech will be responsible for commercial production at its new Reykjavik facility, where it will scale up and perform process validation.
Mark Levick, Alvotech’s chief executive officer, said in a statement that the partnership “marks an important milestone for our company as we work towards expanding our contract manufacturing business. We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
The deal is the latest in a string of agreements related to biosimilars for Prestige, which in July entered into an exclusive agreement with Pharmapark LLC to supply and commercialize Prestige’s trastuzumab biosimilar, HD201, in Russia.
The Pharmapark deal came on the heels of an agreement with Mundipharma to license and supply the same biosimilar in parts of Europe.
In 2018, Prestige announced entered into a licensing agreement with Cipla Limited to distribute and market the biosimilar trastuzumab in some emerging markets, and even earlier, Prestige inked a deal with Alvogen to commercialize the biosimilar in Central and Eastern Europe.
In May of this year, the European Medicines Agency accepted for review a Marketing Authorization Application for HD201, and the company is also developing biosimilars referencing bevacizumab, adalimumab, denosumab, aflibercept, eculizumab, and ipilimumab.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
